companies developing glp 1 drugs Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Market Overview: GLP-1 Agonists and
Description
3.9% (obesity) Pregnancy loss higher in all groups with metabolic risk (2329%) Live birth rate: 59% (GLP-1 RA group) Conclusion: Reassuring data with no signal for increased congenital malformations

If you're currently taking GLP-1 medications or following a reduced-calorie diet, your body may require additional support for your bodys cellular energy, bone health, immune health, digestion, and overall wellness

[DOI] [PMC free article] [PubMed] [Google Scholar] 299.Karagiannis T., et al

The index date for this group corresponded to the initial date of their obesity diagnosis

Until now, the most effective versions have been injectables